Use of Tetravalent Galabiose for Inhibition of Streptococcus Suis Serotype 2 Infection in a Mouse Model

Biology

Roland J. Pieters⁴  Hans-Christian Slotved¹  Hanne Møller Mortensen¹  Lene Arler¹  Jukka Finne³  Sauli Haataja²  John A. F. Joosten⁴  Hilbert M. Branderhorst⁴ 

[1] Department of Microbiology and Infection Control (MI), Statens Serum Institut, Copenhagen, Denmark; E-Mails:;Department of Medical Biochemistry and Genetics, University of Turku, Kiinamyllynkatu 10, Turku FI-20520, Finland; E-Mail:;Department of Biosciences, Division of Biochemistry and Biotechnology, University of Helsinki, P.O.B. 56, Helsinki FI-00014, Finland; E-Mail:;Department of Medicinal Chemistry and Chemical Biology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, 3508 TB, Utrecht, The Netherlands; E-Mails:

关键词: tetravalent galabiose;    Streptococcus suis;    adhesion inhibition;    mouse model;   

DOI  :  10.3390/biology2020702

来源: mdpi

【 摘 要 】

Streptococcus suis is an important swine pathogen associated with a variety of infections such as meningitis, arthritis and septicemia. The bacterium is zoonotic and has been found to cause meningitis especially in humans occupationally exposed to infected pigs. Since adhesion is a prerequisite for colonization and subsequent infection, anti-adhesion treatment seems a natural alternative to traditional treatment with antibiotics. In order to optimize the inhibitory potency a multivalency approach was taken in the inhibitor design. A synthetic tetravalent galabiose compound was chosen which had previously shown promising anti-adhesion effects with S. suis in vitro. The aim of this study was to evaluate the in vivo effects of the compound using an infection peritonitis mouse model. As such S. suis serotype 2 infection and treatment were tested in vivo and the effects were compared to the effect of treatment with penicillin.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.